The result is a peptide with substantially extended plasma stability relative to native GHRH while preserving full receptor agonist activity at the human growth hormone-releasing hormone receptor (GHRHR)
Its made by Eli Lilly and was FDA-approved for weight loss in April 2026
Although it could be anticipated that the magnitude of glutathione increases would correlate with behavioral improvements as in other studies ( When examining the relationship between baseline glutathione levels, the responders ( n = 12) had significantly higher baseline concentrations of both total and reduced glutathione than baseline and non-responders ( n = 8)
.,McGlynnKA,WatlingCZ,HernandezBYGroopmanJDEnvironmental risk factors for liver cancer.2025
The answer, while not entirely straightforward, holds the key to understanding the transformative potential of this cutting-edge treatment
However, it also is raising this thought of, are there other mechanisms that are contributing to the benefit